Funded by the European Commission and coordinated by Radboud University, the cornerstone project NatureRestoreR: guiding nature restoration through integrated ecological modelling was officially launched on 1 September 2026. The project carries grant number 101287178 and will be implemented over a four-year period, concluding on 1 September 2030. The primary objective of NatureRestoreR is to provide publicly available ecological modelling tools and guidelines. These resources are intended to enable national and regional authorities to design restoration plans based on a scientifically sound understanding of how species, habitats, and ecosystem services respond to restoration measures in different places and under evolving climate dynamics.

A critical challenge in guiding ecosystem restoration efforts is that there is no single approach to restoring nature. Species and habitats may respond differently to a given restoration measure depending on local environmental conditions. Furthermore, climate change can affect the long-term outcomes of restoration efforts. Consequently, authorities need robust scientific evidence to understand how species and ecosystems are likely to respond to restoration under specific circumstances. They also need to identify where interventions can create synergies or trade-offs. NatureRestoreR seeks to address this challenge by convening existing data, scientific knowledge, and modelling approaches to develop an innovative suite of adaptive and easy-to-use ecological modelling tools.

These modelling tools will enable evidence-based prospective assessment of restoration measures. Specifically, they will model the potential impacts on species’ habitats, the extent and condition of habitats protected under the EU Nature Directives, and the provision of ecosystem services. By providing these insights, the project aims to help decision-makers make more informed choices about where and how to allocate restoration resources. This approach is designed to ensure that restoration efforts are not only ecologically sound but also practically feasible for national and regional authorities.

The development of these modelling tools will be a collaborative effort, co-developed and tested through a co-creation process involving researchers and implementation partners. The project will use information from the initial and final revised National Restoration Plans of five EU Member States: Austria, Italy, France, Estonia, and the Netherlands. This collaborative approach will enable the project partners to assess how these plans contribute to the objective of the EU Biodiversity Strategy and the Nature Restoration Regulation. By working with these specific national plans, the project ensures that the tools are relevant to real-world policy contexts and can be adapted to different national circumstances.

Reflecting on the project’s long-term vision, Aafke Schipper, a member of the coordination team at Radboud University, emphasized the importance of the partnership structure. Schipper noted that NatureRestoreR relies on a unique co-creation partnership between ecological researchers and national authorities responsible for or involved in the implementation of the Nature Restoration Regulation. Through this partnership, the project ensures that it meets the needs of decision-makers and practitioners who are implementing and monitoring the regulation. This focus on user needs is central to the project’s design, aiming to create tools that are not only scientifically rigorous but also practical for those on the ground.

NatureRestoreR’s transdisciplinary partnership brings together ecological modelling experts and national agencies with deep knowledge of the EU Nature Directives and National Restoration Plans. Working together, these partners aim to strengthen the relation between ecological knowledge and the decisions shaping Europe’s landscape. The project recognizes that effective restoration requires a close link between scientific understanding and policy implementation. By integrating these two areas, NatureRestoreR hopes to create a more cohesive approach to ecosystem restoration across the continent. This integration is seen as essential for achieving the ambitious targets set by the EU.

Throughout the project, NatureRestoreR will engage with researchers, practitioners, policymakers, and other stakeholders interested in advancing effective, evidence-informed ecosystem restoration across Europe. This broad engagement is intended to ensure that the project’s outputs are widely accessible and useful to a diverse range of actors involved in nature restoration. The project team encourages stakeholders to follow NatureRestoreR on LinkedIn to stay up to date with the project’s latest news, activities, and results. This ongoing communication is part of the project’s strategy to build a community of practice around evidence-based restoration.

The launch of NatureRestoreR represents a significant step forward in the effort to make nature restoration smarter and more effective in Europe. By providing the tools and evidence needed to design and refine restoration plans, the project aims to support the implementation of the EU Nature Restoration Regulation. The focus on co-creation and transdisciplinary collaboration is expected to ensure that the project’s outputs are relevant and useful to those responsible for implementing restoration measures. As the project progresses over the next four years, it will provide valuable insights into how ecological modelling can be used to guide restoration efforts in a changing climate. The ultimate goal is to contribute to the restoration of Europe’s ecosystems and the achievement of the EU’s biodiversity targets.

Subject of Research: Environmental Policy and Ecology

Article Title: NatureRestoreR launches to support Europe in making nature restoration smarter and more effective

Article References: NatureRestoreR launches to support Europe in making nature restoration smarter and more effective. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Nature Restoration, EU Policy, Ecological Modelling, Biodiversity, Climate Change, Radboud University, European Commission, NatureRestoreR, launches, support, Europe, making

To understand why this regulation matters, it helps to recall how far the underlying science has travelled since the current legal framework was drafted. Directive 2001/18/EC, the main legislation governing the environmental release of genetically modified organisms in the EU, dates back to 2001. At that time, the dominant method for creating a transgenic plant involved inserting foreign DNA more or less at random into the genome, typically through Agrobacterium-mediated transformation or particle bombardment. Regulators built a system around that reality: every organism carrying recombinant DNA was treated as a genetically modified organism, subject to case-by-case risk assessment, traceability requirements and labelling obligations, regardless of the size of the genetic change involved.

The tools available to plant scientists then changed beyond recognition. Site-directed nucleases, and above all the CRISPR-Cas systems that emerged from foundational work in the early 2010s, made it possible to edit genomes with base-pair precision. Researchers could now introduce small deletions, single-nucleotide substitutions or precisely defined insertions at chosen target sites, producing plants whose final genetic makeup may be indistinguishable from what conventional mutagenesis or natural variation could deliver. Oligonucleotide-directed mutagenesis and epigenetic modifications added further routes to targeted change. The conceptual foundation of the 2001 directive, which anchors regulation to the process used rather than the characteristics of the final product, suddenly sat uneasily alongside techniques that blur the line between engineered and naturally occurring variation.

European institutions saw the problem early. The first Working Group on New Plant Breeding Techniques was established by the European Commission in 2007, with the explicit aim of identifying legislation more appropriate to technologies developed after 2001. That group and its successors wrestled with a deceptively simple question: when a genome edit could equally have been produced by conventional breeding, should the plant be regulated as a genetically modified organism? For years the question produced legal opinions, reports and consultations but no binding answer, while breeders in North America, Japan, Argentina and elsewhere moved ahead under product-based or tiered regulatory approaches.

The turning point came from an unexpected direction. In 2018, the Court of Justice of the European Union ruled that organisms obtained by directed mutagenesis techniques fall within the scope of the GMO directive, exempting only those produced by conventional mutagenesis methods that had long been in use. The judgment meant that even a precise, transgene-free edit made with CRISPR was legally equivalent to a transgenic insertion from the 1990s. Scientists and plant breeders warned that the ruling effectively locked European researchers out of the most dynamic area of modern crop improvement, and petitions from the scientific community urged the Commission to revisit the framework. The episode became a defining case study in how process-based regulation can struggle to accommodate technological change.

The Commission responded in 2023 with a legislative proposal that distinguished between categories of plants obtained by new genomic techniques, drawing a line between edits that could have been achieved through conventional breeding and more complex alterations involving foreign genetic material. The proposal triggered intense negotiation over the criteria for the lighter-touch category, the treatment of patents on gene-edited traits, the verification of edits without transgenic intermediates, and the coexistence of new-technique plants with organic and conventional supply chains. Those debates shaped the text that the Council and Parliament ultimately approved, and they explain why adoption took as long as it did.

Regulation (EU) 2026/1388 now provides the operative answer. Plants obtained by certain new genomic techniques, and products derived from them, gain a dedicated legal pathway that reflects the nature and scale of the genetic modification involved. For the plant science community, the significance is as much symbolic as practical: the EU has acknowledged, in binding law, that the regulatory treatment of a plant should depend on what has actually been changed in its genome, not merely on the laboratory method used to change it. That shift in regulatory philosophy, from process to product characteristics, is the intellectual heart of the reform.

The practical consequences will unfold over the coming years. Breeders developing traits such as disease resistance, altered oil profiles, drought tolerance or improved nutritional composition through targeted editing will be able to plan commercialisation strategies under a framework designed for their tools rather than inherited from an earlier technological era. Public research institutes, which were among the loudest voices calling for reform, stand to benefit particularly, since the cost and uncertainty of the old GMO regime weighed most heavily on actors without the resources of multinational seed companies. At the same time, implementation will demand new technical capacities: detection and identification of edited plants in traded goods, verification dossiers, and post-market oversight all require methods and expertise that national authorities are only now beginning to build.

Open scientific questions remain. Distinguishing a targeted edit from spontaneous or induced mutation of the same kind is analytically demanding, and the technical literature continues to explore how sequencing-based and other approaches can support enforcement without imposing prohibitive burdens. The interaction between the new regulation and intellectual property law, especially the patentability of gene-edited traits versus the breeders’ exemption in plant variety rights, remains one of the most contested issues in the field. And the global regulatory landscape is far from harmonised, meaning that exporters and importers will need to navigate divergent definitions and thresholds across jurisdictions for years to come.

What the adoption of Regulation (EU) 2026/1388 demonstrates most clearly is that regulatory systems can, eventually, catch up with science, even if the journey is measured in decades rather than years. From the first Commission working group in 2007 to the final votes in 2026, the EU spent nearly twenty years reconciling a law written for transgenic technology with a world of precise genome editing. For plant scientists who watched the gap widen year after year, the new regulation is not merely a legal text but a signal that evidence-based argument can reshape policy. The challenge now shifts from drafting the rules to implementing them well, so that the promise of new genomic techniques, for agriculture, for research and for food security, can be realised within a framework the public can trust.

Subject of Research: EU regulation of plants developed with new genomic techniques

Article Title: Evolution and implementation of EU regulation on new genomic techniques

Article References: Cardi, T., & Vitale, A. (2026). Evolution and implementation of EU regulation on new genomic techniques. Nature Plants, 12(9), 1650-1655. https://doi.org/10.1038/s41477-026-02402-9

Image Credits: AI Generated

DOI: 10.1038/s41477-026-02402-9

Keywords: new genomic techniques, EU regulation, CRISPR, plant breeding, genetically modified organisms, Directive 2001/18/EC, genome editing, agricultural biotechnology, European Commission, plant science, food security, regulatory policy

From 14 to 16 October 2026, Momentum will bring together European policymakers, researchers, healthcare leaders, patient advocates, industry representatives, civil society, and investors for three days of discussions on how the continent can shorten the path from scientific discovery to clinical practice. The conference is convened by the Swedish Cancer Society, an independent non-profit organisation that is marking 75 years of supporting advances in cancer research and patient care. The choice of Stockholm as the venue and the timing of the event reflect a deliberate statement: progress in oncology is no longer limited by the pace of discovery alone, but by the speed with which health systems can absorb and deploy what science has already produced.

The scale of the challenge is well documented. Survival outcomes for many cancers have improved dramatically over the past half-century, and in Sweden, according to the Swedish Cancer Society, cancer survival rates have more than doubled, with seven out of ten people diagnosed with cancer today surviving their disease. Yet these gains are unevenly distributed across Europe, and the lag between the moment a research advance is validated and the moment it becomes standard practice for patients can stretch across years. During that interval, patients are treated with older tools while newer, potentially more effective options sit in pipelines, awaiting decisions on regulation, pricing, reimbursement, and clinical guideline updates.

The speaker list assembled for Momentum 2026 signals the breadth of expertise the organisers believe is required. Among the confirmed speakers is Greg Simon, former Executive Director of the White House Cancer Moonshot Task Force, whose work in the United States focused on accelerating cancer research through coordinated national effort. From the European institutional side, Joanna Drake, Deputy Director-General at the European Commission’s Directorate-General for Research and Innovation, will bring the perspective of the body that shapes much of the continent’s research funding and policy agenda. Cary Adams, Chief Executive Officer of the Union for International Cancer Control, and Elisabete Weiderpass, Director General of the International Agency for Research on Cancer, represent the global health and research organisations that sit at the intersection of science, public health, and international cooperation.

Simon, in remarks published ahead of the conference by the Swedish Cancer Society, framed the central problem in stark terms. “The bottleneck is time,” he said. “Every year we spend moving a discovery through regulatory, reimbursement, and clinical trial bureaucracies is a year patients don’t have.” His assessment captures the frustration shared by many in the oncology community: the science itself is often ready well before the systems around it are. Simon added, “The next breakthrough won’t come from a single lab – it will come from collapsing the distance between discovery and patient.”

Perhaps more revealing than Simon’s diagnosis of the problem is his description of what he hopes to achieve in Stockholm. “I want to leave Sweden with at least one conversation that changes how I think about something. Not panels – conversations,” he said. That emphasis on dialogue over presentation reflects a growing recognition among conference organisers in the health policy space that the barriers to faster adoption of research are not primarily technical. They are human, institutional, and political, involving misaligned incentives, slow information flows between sectors, and the absence of forums where the people who fund research, the people who regulate it, the people who deliver care, and the people who live with cancer can speak to one another directly.

Momentum’s programme is deliberately structured around that premise. The conference brings together what the organisers describe as a carefully curated group of leaders across sectors, all with a shared ambition to accelerate Europe’s action on cancer. Rather than segregating scientists into academic sessions and policymakers into political ones, the format is designed to force these constituencies into the same conversations, on the theory that the solutions to slow adoption will emerge from people who understand both what the science makes possible and what the health system can realistically absorb. The organisers frame the gap between research, decision-making, and real-world impact as “one of our greatest missed opportunities” – language that acknowledges the human cost of delay in a disease area where time is often the most precious resource a patient has.

The conference will also feature a panel of leading journalists providing commentary and reflections throughout the three days, including Sarah Neville, Global Health Editor at the Financial Times; Alexandra Ivanov Hökmark, Associate Editor at Dagens industri; and Helena Smolak, Pharma Correspondent at Handelsblatt. The inclusion of financial and pharmaceutical journalism alongside health policy reporting is notable, because the economics of cancer innovation – who pays for it, who profits from it, and who can afford to benefit from it – are inseparable from the question of how quickly advances reach patients. Journalistic scrutiny of those dynamics, conducted in real time during the conference itself, may add a layer of accountability and public visibility that traditional scientific meetings rarely generate.

The institutional machinery behind Momentum adds weight to its ambitions. The Swedish Cancer Society, known in Sweden as Cancerfonden, has contributed 18 billion Swedish kronor to Swedish cancer research since its founding and describes its mission as funding the highest quality research, spreading knowledge about cancer, and influencing decision-making in key areas so that fewer people are affected and more people survive. Its decision to convene a European policy conference as it marks its 75th anniversary suggests a strategic evolution for organisations like it: the recognition that funding excellent research is necessary but insufficient, and that philanthropy and patient advocacy now have a role to play in reshaping the systems that translate research into care.

Whether Momentum 2026 produces concrete change will depend on what follows the closing session in Stockholm. Conferences of this kind are often judged by whether they generate durable commitments: cross-border collaborations that outlast the event, policy proposals taken up by the European Commission, or pilot programmes that test faster pathways for integrating research advances into clinical practice. The speakers and organisers have set a high bar for themselves, framing the problem not as a lack of scientific progress but as a failure of translation and coordination. If the conversations Simon is seeking – the ones that change how people think – take root among the policymakers, funders, and health leaders in attendance, the event may be remembered less for what was presented on stage and more for what was set in motion afterwards. For Europe’s cancer patients, who stand to gain or lose the most from how quickly science reaches them, the stakes of that outcome could not be higher.

Subject of Research: Accelerating the translation of cancer research into patient benefit in Europe

Article Title: Momentum: Turning cancer research into patient benefit across Europe

Article References: Momentum: Turning cancer research into patient benefit across Europe. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Momentum 2026, cancer research, Europe, health policy, Swedish Cancer Society, Stockholm, patient advocacy, clinical translation, oncology, European Commission, health systems, research funding

The study, conducted by Antonio Puertas Gallardo and Magdalena Stepien of the European Commission’s Joint Research Centre in Ispra, Italy, together with Antonino Brunetto of ARHS Developments Italia in Milan, examined 102 projects funded under Horizon Europe, the EU4Health programme, and the Digital Europe Programme. Together, these initiatives represent a combined investment of more than 840 million euros dedicated to understanding, detecting, treating and preventing cancer. The work is significant not merely for its headline figures but for its methodology, which demonstrates how modern artificial intelligence tools can bring order to the sprawling, fragmented record of publicly funded research.

The researchers employed a combination of quantitative and qualitative methods to characterise the funding landscape and identify patterns within it. The centrepiece of their approach was the application of large language model methodology to assign standardised keywords to each project in the portfolio. This was no trivial task. EU-funded cancer projects span an enormous range of activities, from laboratory-based investigations of tumour biology to public health campaigns and the construction of digital infrastructure for sharing clinical data. Without a common vocabulary, comparing projects across different programmes and directorates-general becomes nearly impossible, and opportunities for synergy go unnoticed.

By using large language models to read and classify project descriptions, the team developed a set of 56 standardised keywords capable of clustering the 102 projects into coherent thematic groups. This keyword framework allowed the researchers to identify synergies and thematic interconnections among cancer-related initiatives that would otherwise remain buried in separate databases and reporting formats. The most frequent terms to emerge from this analysis related to healthcare, policy and guidance, and digital aspects, reflecting the fact that EU cancer funding is not confined to the bench but extends deep into health systems, regulation and technology.

The thematic findings offer a revealing snapshot of European priorities. Most of the funded projects concentrated on diagnosis, treatment and prevention, the three pillars of clinical oncology. When the analysis turned to specific cancer types, colorectal and breast cancers emerged as the most common areas of focus, a pattern consistent with their status as two of the most frequently diagnosed malignancies in Europe and with the existence of dedicated screening programmes across many member states. The prominence of digital keywords underscores how thoroughly data science, artificial intelligence and e-health technologies have penetrated the cancer research agenda, from computational pathology platforms to federated networks for sharing sensitive patient information.

Equally striking were the geographic patterns the analysis uncovered. Institutions from larger western and southern European countries proved to be the most active participants in EU cancer funding, dominating both the coordination of projects and participation more broadly. Distinct collaboration networks between specific institutions were identified, revealing clusters of organisations that repeatedly join forces across successive funding calls. These networks represent a form of institutional capital that is invisible in simple funding statistics but crucial to understanding how European research capacity is actually organised and reproduced over time.

Perhaps the most politically consequential finding concerns the relationship between national characteristics and funding success. The study found that countries with larger populations were involved in a greater number of projects, but that countries with a higher gross domestic product per capita were not. In other words, wealth per citizen does not predict engagement with EU cancer funding, but sheer demographic weight does. This distinction matters for ongoing debates about the equity of EU research funding. Smaller member states have long voiced concerns that framework programmes disproportionately reward large, well-established research systems, and this analysis provides granular evidence with which such concerns can now be assessed and, potentially, addressed through targeted policy interventions.

The technical achievement underlying these findings deserves attention in its own right. Assigning standardised keywords to research projects has traditionally been a labour-intensive exercise requiring expert panels to read and code hundreds of project abstracts, a process that is slow, expensive and difficult to reproduce. Large language models, by contrast, can process project descriptions at scale and apply a consistent classification scheme, making it feasible to update the mapping continuously as new projects are funded. The authors’ use of this technology within an official Commission analysis signals a broader shift in how public administrations may approach evidence-based policymaking, treating the text of research proposals and reports not as administrative residue but as analysable data.

The practical implications extend beyond academic interest. The European Commission’s cancer projects tool, which provided the data for this study, is designed to give policymakers, researchers and the public a transparent view of EU cancer funding. By demonstrating how the tool’s contents can be systematically analysed, the authors have laid what they describe as the foundation for more strategic planning of EU cancer funding. Identifying thematic clusters makes it possible to spot both overcrowded areas, where additional investment may yield diminishing returns, and neglected ones, where gaps in the portfolio may warrant attention in future work programmes. Mapping collaboration networks similarly allows funders to see which institutions are consistently included and which remain on the margins of European cancer research.

The study arrives at a moment when Europe’s ambition to reduce the cancer burden is codified in policy initiatives spanning research, health systems and digital infrastructure. What this analysis makes clear is that ambition is backed by substantial and traceable resources: more than 840 million euros distributed across 102 projects spanning three complementary programmes. What it also makes clear is that the distribution of those resources follows identifiable structural patterns, shaped by population size, institutional networks and thematic fashion. By making those patterns visible, the Joint Research Centre team has transformed a collection of individual project records into a strategic instrument, one that could help ensure that the next generation of European cancer funding is planned not by habit or accident, but by design.

Subject of Research: Analysis of European Union cancer research funding across Horizon Europe, EU4Health and the Digital Europe Programme

Article Title: Unveiling European cancer funding: insights from the European Commission’s cancer projects tool

Article References: Puertas Gallardo, A., Brunetto, A., & Stepien, M. (2026). Unveiling European cancer funding: insights from the European Commission’s cancer projects tool. Health Research Policy and Systems. https://doi.org/10.1186/s12961-026-01535-9

Image Credits: AI Generated

DOI: 10.1186/s12961-026-01535-9

Keywords: cancer funding, Horizon Europe, EU4Health, Digital Europe Programme, large language models, European Commission, Joint Research Centre, cancer policy, research collaboration, colorectal cancer, breast cancer, health research policy